The endocannabinoid system is one of the least-known regulatory networks in the human body, despite playing a role in sleep, pain, mood, appetite, memory, and immune function. Most Australians have never heard of it. That's partly because it wasn't discovered until the early 1990s, and partly because it's been caught up in debates about cannabis. The system exists in every human body, whether you've ever used cannabis or not.
What the endocannabinoid system actually is
The endocannabinoid system (ECS) is a cell-signalling network made up of three core components: endocannabinoids, receptors, and enzymes. Each part plays a specific role, and together they help the body maintain internal balance, a process scientists call homeostasis.
Endocannabinoids are molecules your body produces on its own. The two most studied are anandamide and 2-arachidonoylglycerol (2-AG). Both are lipid-based molecules built from fats, and they act as chemical messengers. They're made on demand and broken down quickly once they've done their job.
Receptors are the targets these messengers bind to. CB1 receptors sit mostly in the brain and central nervous system. CB2 receptors are found mostly in immune tissues and peripheral organs. When an endocannabinoid locks onto a receptor, it triggers a cellular response. The type of response depends on where in the body the receptor is located.
Enzymes then break the endocannabinoids down after use. FAAH breaks down anandamide. MAGL handles 2-AG. This breakdown is what stops the signal from running too long.
How it differs from other neurotransmitter systems
Most signalling in the brain runs in one direction: a neuron fires, releases a chemical, and the receiving neuron picks it up. The ECS works in reverse. The receiving neuron produces endocannabinoids and sends them back to the firing neuron, telling it to slow down or change its output. This is called retrograde signalling, and it makes the ECS a kind of feedback brake on neural activity.
That's significant. It means the ECS doesn't initiate signals so much as it modulates them. It damps excess activity, fine-tunes responses, and helps the nervous system avoid going too hard in one direction.
Cortisol, for instance, triggers a stress response throughout the body. The ECS helps put the brakes on that response once the threat has passed. If you've read about what cortisol does to your body, the ECS is part of what keeps that hormone in check over time.
What the ECS regulates
The ECS has a hand in a wide range of physiological processes. The most well-supported by research include:
- Sleep: anandamide builds up in the brain during waking hours and plays a role in triggering sleep pressure. CB1 receptor activity in the hypothalamus influences sleep-wake cycles.
- Pain perception: ECS signalling in the spinal cord and brain modulates how pain signals are processed, which is why CB1 agonists can reduce pain without the same mechanism as opioids.
- Mood and stress: the amygdala, which processes fear and anxiety, is dense with CB1 receptors. Endocannabinoid activity there influences emotional memory and the body's recovery from stressful events.
- Appetite and metabolism: the hypothalamus uses ECS signals to regulate hunger. 2-AG, in particular, has been linked to appetite stimulation.
- Immune response: CB2 receptors on immune cells let the ECS influence inflammation, playing a modulatory role in conditions where the immune system is overactive.
The link to sleep and circadian rhythms
One of the more interesting areas of ECS research involves its relationship to circadian rhythm, the internal 24-hour clock that governs when you feel alert and when you feel tired. Anandamide levels follow a daily pattern, peaking in the evening in some brain regions. CB1 receptor sensitivity also shifts across the day. This suggests the ECS doesn't just respond to sleep pressure but is woven into the timing system itself.
Disruptions to this timing, whether from shift work, jet lag, or chronic stress, appear to affect ECS tone. Lower anandamide levels have been documented in people with anxiety disorders and in animal models of sleep deprivation.
Why cannabis affects this system
THC (tetrahydrocannabinol), the primary psychoactive compound in cannabis, binds to CB1 receptors with far greater potency than the body's own endocannabinoids. It essentially floods the system. That's why cannabis can produce intense effects on mood, perception, appetite, and memory. The system wasn't designed to handle that level of activation.
CBD (cannabidiol), by contrast, doesn't bind directly to CB1 or CB2 receptors. It's thought to influence the ECS indirectly, partly by slowing the breakdown of anandamide. That's a much more subtle effect, which is why the science on CBD's therapeutic role is still genuinely contested.
The fact that cannabis affects this system so powerfully is what led researchers in the early 1990s to discover the ECS in the first place. Israeli researcher Raphael Mechoulam and his team at the Hebrew University of Jerusalem identified anandamide in 1992, building on decades of work isolating THC. The body's system was named in part because of what plant cannabinoids revealed about it.
Clinical implications still being worked out
The ECS is now a serious target for pharmaceutical research. Drugs that modify CB1 or CB2 activity, or that slow the breakdown of endocannabinoids, are being investigated for pain, epilepsy, inflammatory conditions, and mental health disorders. Epidiolex, a CBD-based drug, received approval from the US Food and Drug Administration in 2018 for two severe forms of epilepsy, making it the first cannabis-derived medicine to clear that process.
There's also growing interest in the concept of "clinical endocannabinoid deficiency," a hypothesis put forward by Mechoulam and later expanded by American neurologist Ethan Russo. The idea is that some conditions, including migraine, irritable bowel syndrome, and fibromyalgia, may involve chronically low ECS tone. It's a contested hypothesis. But the pattern of overlapping symptoms and the ECS's role in all three areas keeps researchers interested.
What's not contested is that the ECS exists, is active in virtually every tissue in the body, and does far more than most health education has ever acknowledged. For a system this widespread, the gap between what scientists know and what the public understands is unusually large.
That gap is closing. Research into the ECS has accelerated since 2015, and the picture is becoming clearer: this is a regulatory system as important as the endocrine or immune systems, and understanding it changes how researchers think about pain, sleep, stress, and a lot of the conditions tied to those experiences. Worth knowing about, whether or not cannabis is part of the picture.
If you want to understand how the body handles chronic stress responses more broadly, the article on what stress actually does to your body covers the physiological chain in more detail.